N-[(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-tris(3-aminopropoxy)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentyl]undecan-1-amine

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: N-[(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-tris(3-aminopropoxy)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentyl]undecan-1-amine
• 化学式: C₄₄H₈₆N₄O₃
• 分子量: 719.2
• InChiKey: VVCCPALFQHPJAF-YBPGUCNXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.9
• 重原子数：
  51
• 可旋转键数：
  27
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  118
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• METHODS FOR THE SYNTHESIS OF CERAGENINS
  申请人：Savage Paul B.

  公开号：US20160311851A1

  公开（公告）日：2016-10-27

  Disclosed herein are methods of making ceragnenin compounds for treating, preventing, or diagnosing diseases, disorders, or conditions associated with bacterial or viral infections, cancer, inflammation, and osteogenesis. Ceragenin compounds display broad-spectrum antibacterial activity utilizing a mode of action similar to antimicrobial peptides, but without the high synthesis costs and susceptibility to proteolytic degradation. Ceragenin compounds reproduce the amphiphilic morphology found in many antimicrobial peptides and display potent and diverse biological activities, including anti-bacterial, anti-cancer, anti-inflammatory, bone growth promotion, and wound healing promotion.

  本公开涉及一种用于治疗、预防或诊断与细菌或病毒感染、癌症、炎症和骨生成相关的疾病、疾病或状况的方法。Ceragenin化合物展示了广谱抗菌活性，利用类似于抗菌肽的作用方式，但不具有高合成成本和易受蛋白酶降解的特性。Ceragenin化合物复制了许多抗菌肽中发现的两性形态，并展示出强大而多样的生物活性，包括抗菌、抗癌、抗炎、促进骨生长和促进伤口愈合。
• CATIONIC STEROIDAL ANTIMICROBIAL PRODRUG COMPOSITIONS AND USES THEREOF
  申请人：Savage Paul B.

  公开号：US20160096864A1

  公开（公告）日：2016-04-07

  Prodrugs or pharmaceutically acceptable salts, stereoisomers, solvates, or polymorphs thereof include a pharmaceutically and/or diagnostically active cationic steroidal antimicrobial (hereinafter “CSA”) compound or pharmaceutically acceptable salt, stereoisomer, solvate, or polymorph thereof, and one or more cleavable groups (C.G.). Some embodiments include a CSA compound prepared in an inactive or less active form and that is capable of conversion to a fully active form upon administration to a subject, upon preparation of a pharmaceutical formulation containing the CSA composition, and/or upon exposure to physiological conditions. Pharmaceutical compositions include the prodrug or pharmaceutically acceptable salt, stereoisomer, solvate, or polymorph thereof and one or more pharmaceutically acceptable excipients. Methods of treatment of bacterial infections in a patient in need utilize prodrugs or pharmaceutically acceptable salts, stereoisomers, solvates, polymorphs thereof and/or the pharmaceutical compositions described herein.

  前药或药学上可接受的盐、立体异构体、溶剂化物或其多晶体包括一种药学上和/或诊断上活性的阳离子类固醇抗微生物化合物（以下简称“CSA”）化合物或药学上可接受的盐、立体异构体、溶剂化物或其多晶体，以及一个或多个可裂解基团（C.G.）。一些实施例包括以不活性或较不活性形式制备的CSA化合物，该化合物能够在给予受试者、制备含有CSA组分的制药配方和/或暴露于生理条件下时转化为完全活性形式。制药组合物包括前药或药学上可接受的盐、立体异构体、溶剂化物或其多晶体以及一个或多个药学上可接受的辅料。需要治疗细菌感染的患者的治疗方法利用前药或药学上可接受的盐、立体异构体、溶剂化物、多晶体和/或本文所述的制药组合物。
• Compositions and methods for forming stabilized compositions with reduced CSA agglomeration
  申请人：Darien Benjamin J.

  公开号：US10220045B2

  公开（公告）日：2019-03-05

  Compositions and methods for preparing stabilized CSA compositions having reduced agglomeration and increased stability. The compositions have increased efficacy in killing microbes and reduced cytotoxicity to mammals. The compositions include a liquid carrier, micelles formed from an amphiphilic material, and CSA molecules encapsulated by the micelles. The CSA compositions can be formed by blending together a solvent or liquid carrier, a plurality of CSA molecules, and a micelle-forming agent and causing or allowing the micelle-forming agent to form micelles encapsulating at least a portion of the CSA molecules so that no more than 25% of the CSA molecules form agglomerates larger than 1 μm in size. The CSA compositions can be used to treat mammals, such as mammals suffering from microbial diseases or infections.

  用于制备稳定 CSA 组合物的成分和方法，可减少结块并提高稳定性。这些组合物具有更强的杀灭微生物的功效，并降低了对哺乳动物的细胞毒性。组合物包括液体载体、由两亲性材料形成的胶束以及被胶束包裹的 CSA 分子。CSA 组合物可以通过将溶剂或液体载体、多种 CSA 分子和胶束形成剂混合在一起，并使或允许胶束形成剂形成胶束包裹至少一部分 CSA 分子，从而使不超过 25% 的 CSA 分子形成大小超过 1 μm 的团块来形成。CSA 组合物可用于治疗哺乳动物，如患有微生物疾病或感染的哺乳动物。
• METHODS FOR TREATING LUNG INFECTIONS AND INFLAMMATION
  申请人：SAVAGE PAUL B.

  公开号：US20150110767A1

  公开（公告）日：2015-04-23

  Methods of treating, reducing, or preventing lung infections or lung inflammation include identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Treatment of cystic fibrosis lung infections, COPD lung infections, inflammation of the lungs in these patient populations, and lung scarring in these patient populations is also described.
• CATIONIC STEROIDAL ANTIMICROBIALS
  申请人：Savage Paul B.

  公开号：US20150203527A1

  公开（公告）日：2015-07-23

  Disclosed herein are cationic steroidal antimicrobials (“CSA compounds” or “ceragenins”) and methods of making the same. Particularly advantageous methods are identified for the synthesis of CSA compounds. CSA compounds may be formulated for treating subjects with ailments responsive to CSA compounds, including but not limited to treating bacterial infections. Accordingly, some embodiments include formulations and methods of administering CSA compounds.